Schizophrenia Research
Schizophrenia is a chronic, debilitating mental disorder affecting 1-2% of the global population. Symptoms are split into two types; 'positive' symptoms, including delusions and hallucinations, and 'negative' symptoms, including anhedonia and lack of motivation. Studies suggest that genetics, early environment, neurobiology, psychological and social processes are important contributory factors; some recreational and prescription drugs appear to cause or worsen symptoms. Several neurobiological alterations in brain structure, physiology and neurochemistry have been documented, along with an ever-increasing list of susceptibility genes.
Schizophrenia Research Products Targets
- Others (13)
- Sigma2 Receptor (4)
- Sigma1 Receptor (16)
- D4 Receptor (12)
- 5-HT7 Receptor (11)
- 5-HT6 Receptor (14)
- 5-ht5 Receptor (2)
- 5-HT4 Receptor (17)
- Glutamate (Metabotropic) Group III Receptor (26)
- Glutamate (Metabotropic) Group II Receptor (33)
- Glutamate (Metabotropic) Group I Receptor (54)
- AMPA Receptor (45)
- GABAA-ρ Receptor (8)
- GABAA Receptor (66)
- GPR55 (8)
- CB2 Receptor (6)
- CB1 Receptor (17)
- Nicotinic (α7) Receptor (25)
- Nicotinic (α4β2) Receptor (14)
- D3 Receptor (12)
- NK3 Receptor (5)
- Carboxypeptidase (1)
- NMDA Receptor (87)
- Kainate Receptor (22)
- D2 Receptor (14)
- D1 and D5 Receptor (16)
- Trace Amine 1 Receptor (2)
- Glutamate Transporter (18)
- Histamine H3 Receptor (22)
- Neurotensin Receptor (7)
- Monoamine Oxidase (10)
- iNOS (11)
- M5 Receptor (2)
- M4 Receptor (3)
- M3 Receptor (4)
- M2 Receptor (5)
- M1 Receptor (8)
- Adrenergic α2 Receptor (33)
- Adrenergic α1 Receptor (22)
- Adrenergic β3 Receptor (12)
- Adrenergic β2 Receptor (6)
- Adrenergic β1 Receptor (7)
- Protein serine and threonine phosphatase (16)
- Protein Arginine Methyltransferase (2)
- Phosphodiesterase (34)
Products for Schizophrenia Research - Page 48
- Cat.No. Product Name Information/Activity
-
BCC6378
Talampanel(LY300164)
Talampanel is a potent and selective AMPA-receptor antagonist, is a potential new antiepileptic drug (AED).
-
BCC7171
UBP 282
544697-47-4
-
BCC7455
YM 90K hydrochloride
154164-30-4
-
BCC7339
ZK 200775
Fanapanel (ZK200775) is a highly selective AMPA/kainate antagonist with little activity against NMDA; have Ki values of 3.2 nM, 100 nM, and 8.5 μM against quisqualate, kainate, and NMDA, respectively.
-
BCC6151
CMPDA
CMPDA is a positive allosteric modulator of AMPA receptors with EC50s of 45.4 ± 4.2 nM/63.4 ± 5.6 nM for GluA2i/GluA2o receptor.
-
BCC7532
CX 546
CX546 is a selective positive AMPAR modulator; the prototypical ampakine agent.
-
BCC6759
Cyclothiazide
2259-96-3
-
BCC5951
PEPA
PEPA is an allosteric modulator of AMPA receptors; binds to the GluA2o and GluA3o LBDs and can be utilized as an indicator of AMPA receptor heterogeneity.
-
BCC6322
PF 4778574
PF-4778574 is a positive allosteric modulation of AMPA receptor with EC50 of 45 to 919 nM in differenct cells.
-
BCC6081
S 18986
S 18986 is a selective, orally active, brain penetrant positive allosteric modulator of AMPA-type receptors. S 18986 shows cognitive enhancing properties in rodents. S 18986 activates the release of noradrenaline and acetylcholine in rat hippocampus and enhances rat memory in object-recognition tests.


